Therapeutic strategies for spinal muscular atrophy: SMN and beyond

Therapeutic strategies for spinal muscular atrophy: SMN and beyond

Pokaži ostale verzije (1)

Spinal muscular atrophy (SMA) is a devastating neuromuscular disorder characterized by loss of motor neurons and muscle atrophy, generally presenting in childhood. SMA is caused by low levels of the survival motor neuron protein (SMN) due to inactivating mutations in the encoding gene SMN1. A second...

Bibliografski detalji
Glavni autori:	Bowerman, M, Becker, C, Yáñez-Muñoz, R, Ning, K, Wood, M, Gillingwater, T, Talbot, K, UK SMA Research Consortium
Format:	Journal article
Izdano:	Company of Biologists 2017

Slični predmeti

Therapeutic strategies for spinal muscular atrophy: SMN and beyond
od: Bowerman, M, i dr.
Izdano: (2017)

Therapeutic strategies for spinal muscular atrophy: SMN and beyond
od: Melissa Bowerman, i dr.
Izdano: (2017-08-01)

Targeting the 5' untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy
od: Winkelsas, AM, i dr.
Izdano: (2021)

Targeting the 5′ untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy
od: Audrey M. Winkelsas, i dr.
Izdano: (2021-03-01)

SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy.
od: Wishart, T, i dr.
Izdano: (2010)

Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape
od: Wood, M, i dr.
Izdano: (2017)

SMN post-translational modifications in spinal muscular atrophy
od: Giulietta M. Riboldi, i dr.
Izdano: (2023-02-01)

Spinal muscular atrophy in Venezuela: quantitative analysis of SMN1 and SMN2 genes
od: Yuri Yépez, i dr.
Izdano: (2020-06-01)

Molecular Crosstalk Between Non-SMN-Related and SMN-Related Spinal Muscular Atrophy
od: Darija Šoltić, i dr.
Izdano: (2020-03-01)

The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy.
od: Sleigh, J, i dr.
Izdano: (2011)

Therapy Development for Spinal Muscular Atrophy in SMN Independent Targets
od: Li-Kai Tsai
Izdano: (2012-01-01)

CORRIGENDUM to Molecular Crosstalk Between Non-SMN-Related and SMN-Related Spinal Muscular Atrophy
Izdano: (2020-04-01)

The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs
od: Niko Hensel, i dr.
Izdano: (2020-02-01)

Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy
od: Tejal Aslesh, i dr.
Izdano: (2022-01-01)

SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy
od: Valeria Valsecchi, i dr.
Izdano: (2023-11-01)

The spinal muscular atrophy disease protein SMN is linked to the Golgi network.
od: Chen-Hung Ting, i dr.
Izdano: (2012-01-01)

In Vivo Translatome Profiling in Spinal Muscular Atrophy Reveals a Role for SMN Protein in Ribosome Biology
od: Paola Bernabò, i dr.
Izdano: (2017-10-01)

Patient-specific responses to SMN2 splice-modifying treatments in spinal muscular atrophy fibroblasts
od: Ilaria Signoria, i dr.
Izdano: (2024-12-01)

Quantitative and structural features of the SMN1 and SMN2 genes in patients with spinal muscular atrophy 5q
od: A. I. Vlasenko, i dr.
Izdano: (2024-12-01)

A single amino acid residue regulates PTEN-binding and stability of the spinal muscular atrophy protein SMN
od: Rademacher, S, i dr.
Izdano: (2020)

Spinal muscular atrophy.
od: Talbot, K, i dr.
Izdano: (2001)

Targeting SR proteins improves SMN expression in spinal muscular atrophy cells.
od: Claribel D Wee, i dr.
Izdano: (2014-01-01)

The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy
od: James N. Sleigh, i dr.
Izdano: (2011-07-01)

Molecular and Epidemiological Characterization of SMN Genes in Cuban Patients with Spinal Muscular Atrophy
od: Fabián Lombillo-Alfonso, i dr.
Izdano: (2020-01-01)

Molecular And Epidemiological Characterization Of SMN Genes In Cuban Patients With Spinal Muscular Atrophy
od: Fabián Lombillo, i dr.
Izdano: (2019-05-01)

What could be the function of the spinal muscular atrophy-causing protein SMN in macrophages?
od: Ines Tapken, i dr.
Izdano: (2024-05-01)

Development and Translation of Therapies for Spinal Muscular Atrophy
od: Hannah K. Shorrock, i dr.
Izdano: (2016-07-01)

Review: neuromuscular synaptic vulnerability in motor neurone disease: amyotrophic lateral sclerosis and spinal muscular atrophy.
od: Murray, L, i dr.
Izdano: (2010)

Targeting the 5' untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy
od: Winkelsas, AM
Izdano: (2020)

Abnormal motor phenotype in the SMNΔ7 mouse model of spinal muscular atrophy
od: Matthew E.R. Butchbach, i dr.
Izdano: (2007-08-01)

A Single Amino Acid Residue Regulates PTEN-Binding and Stability of the Spinal Muscular Atrophy Protein SMN
od: Sebastian Rademacher, i dr.
Izdano: (2020-11-01)

The neuromuscular impact of symptomatic SMN restoration in a mouse model of spinal muscular atrophy
od: W. Arnold, i dr.
Izdano: (2016-03-01)

Gene therapy for spinal muscular atrophy: perspectives on the possibility of optimizing SMN1 delivery to correct all neurological and systemic perturbations
od: Sharon J. Brown, i dr.
Izdano: (2025-07-01)

Stability and Oligomerization of Mutated SMN Protein Determine Clinical Severity of Spinal Muscular Atrophy
od: Niba, Emma Tabe Eko, i dr.
Izdano: (2022)

Stability and Oligomerization of Mutated SMN Protein Determine Clinical Severity of Spinal Muscular Atrophy
od: Niba, Emma Tabe Eko, i dr.
Izdano: (2022)

P719: SMN1 deletion and silent carrier screening for spinal muscular atrophy
od: Poh San Lai, i dr.
Izdano: (2024-01-01)

Investigation of a recombinant SMN protein delivery system to treat spinal muscular atrophy
od: Anderton Ryan, i dr.
Izdano: (2014-03-01)

Targeting RNA structure in SMN2 reverses spinal muscular atrophy molecular phenotypes
od: Amparo Garcia-Lopez, i dr.
Izdano: (2018-05-01)

Analysis of the survival of motor neuron (SMN1) gene mutations in Spinal Muscular Atrophy through models
od: Owen, N, i dr.
Izdano: (2002)

Chapter 16 Spinal Muscular Atrophy
od: Talbot, K, i dr.
Izdano: (2003)